Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Divi’s Laboratories Limited ( (IN:DIVISLAB) ) is now available.
Divi’s Laboratories Limited has submitted to the National Stock Exchange of India and BSE Limited the quarterly compliance certificate required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, issued by its registrar and share transfer agent KFin Technologies Limited, confirms that all securities received for dematerialisation during the quarter were appropriately processed, either accepted or rejected, duly listed on the recognised stock exchanges, and that physical certificates were mutilated and cancelled with depositories recorded as registered owners within the prescribed 15-day period, underscoring the company’s adherence to regulatory and corporate governance standards in handling its share capital.
More about Divi’s Laboratories Limited
Divi’s Laboratories Limited is an Indian pharmaceutical company engaged in the manufacture of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients, catering to global generic and innovator drug markets. The company is listed on both the National Stock Exchange of India and BSE Limited, reflecting its position as a significant player in the Indian listed pharma space.
Average Trading Volume: 8,917
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1697.6B INR
For detailed information about DIVISLAB stock, go to TipRanks’ Stock Analysis page.